ES556738A0 - Un procedimiento para la preparacion de nuevos piridazinaminas. - Google Patents

Un procedimiento para la preparacion de nuevos piridazinaminas.

Info

Publication number
ES556738A0
ES556738A0 ES556738A ES556738A ES556738A0 ES 556738 A0 ES556738 A0 ES 556738A0 ES 556738 A ES556738 A ES 556738A ES 556738 A ES556738 A ES 556738A ES 556738 A0 ES556738 A0 ES 556738A0
Authority
ES
Spain
Prior art keywords
piridazinamines
procedure
preparation
new
new piridazinamines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES556738A
Other languages
English (en)
Other versions
ES8802151A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of ES8802151A1 publication Critical patent/ES8802151A1/es
Publication of ES556738A0 publication Critical patent/ES556738A0/es
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22Nitrogen and oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES556738A 1985-07-31 1986-06-25 Un procedimiento para la preparacion de nuevos piridazinaminas. Expired ES8802151A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76084585A 1985-07-31 1985-07-31

Publications (2)

Publication Number Publication Date
ES8802151A1 ES8802151A1 (es) 1988-04-01
ES556738A0 true ES556738A0 (es) 1988-04-01

Family

ID=25060338

Family Applications (1)

Application Number Title Priority Date Filing Date
ES556738A Expired ES8802151A1 (es) 1985-07-31 1986-06-25 Un procedimiento para la preparacion de nuevos piridazinaminas.

Country Status (18)

Country Link
EP (1) EP0211457A3 (es)
JP (1) JPS6229575A (es)
KR (1) KR870001192A (es)
CN (1) CN86105558A (es)
AU (1) AU6073986A (es)
DK (1) DK363186A (es)
ES (1) ES8802151A1 (es)
FI (1) FI863120A (es)
GR (1) GR862022B (es)
HU (1) HU195501B (es)
IL (1) IL79549A0 (es)
NO (1) NO863083L (es)
NZ (1) NZ216918A (es)
PH (1) PH22884A (es)
PT (1) PT83098B (es)
TN (1) TNSN86117A1 (es)
ZA (1) ZA865700B (es)
ZW (1) ZW14886A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY104343A (en) * 1987-11-23 1994-03-31 Janssen Pharmaceutica Nv Novel pyridizinamine deravatives
US4992433A (en) * 1987-11-23 1991-02-12 Janssen Pharmaceutica N.V. Novel pyridazinamine derivatives
GB8911158D0 (en) * 1989-05-16 1989-07-05 Janssen Pharmaceutica Nv Antiviral pyridazinamines
US5070090A (en) * 1989-05-15 1991-12-03 Janssen Pharmaceutica N.V. Antipicorpaviral herterocyclic-substituted morpholinyl alkylphenol ethers
US5270312A (en) * 1990-11-05 1993-12-14 Warner-Lambert Company Substituted piperazines as central nervous system agents
HU226859B1 (en) * 1997-10-27 2009-12-28 Neurosearch As Phenyl- or heteroaryl-homopiperazines, their use and medicaments containing them
CN1348449A (zh) 1999-04-26 2002-05-08 神经研究公司 杂芳基二氮杂环烷烃及其制备方法和应用
EP1430033A4 (en) 2001-08-31 2004-12-15 Univ Northwestern PROTEIN KINASE ANTI-INFLAMMATORY AND INHIBITOR COMPOSITION AND METHOD OF USE
US7390813B1 (en) 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
US7759348B2 (en) 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
ES2568769T3 (es) 2003-07-30 2016-05-04 Xenon Pharmaceuticals Inc. Derivados de piperazina y su uso como agentes terapéuticos
US7754711B2 (en) 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
BRPI0412343A (pt) 2003-07-30 2006-09-05 Xenon Pharmaceuticals Inc derivados de piridazina e seu uso como agentes terapêuticos
AU2005286793A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
AU2005286731A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
EP1804799B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
CA2580856A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
MX2007003325A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa.
AU2016203312B2 (en) * 2004-11-02 2018-05-24 Centre National De La Recherche Scientifique Pyridazine compounds, compositions and methods
EP1812408B1 (en) 2004-11-02 2013-10-09 Northwestern University Pyridazine compounds, compositions and methods
ATE523199T1 (de) 2004-11-02 2011-09-15 Univ Northwestern Pyridazinverbindungen und verfahren
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
CA2650625A1 (en) 2006-04-28 2007-11-08 Northwestern University Formulations containing pyridazine compounds for treating neuroinflammatory diseases
CA2650711A1 (en) 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JP5431306B2 (ja) 2007-04-23 2014-03-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 高速解離性ドパミン2受容体アンタゴニストとしてのチア(ジア)ゾール
MX2009011415A (es) 2007-04-23 2009-11-05 Janssen Pharmaceutica Nv Derivados de 4-alcoxipiridazina como antagonistas del receptor de dopamina 2 de rapida disociacion.
CA2687931C (en) * 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
JP5457450B2 (ja) 2008-07-31 2014-04-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 迅速解離性ドーパミン2受容体拮抗薬としてのピペラジン−1−イル−トリフルオロメチル−置換−ピリジン
US9260400B2 (en) 2011-05-24 2016-02-16 Universita' Degli Studi Di Bari “Aldo Moro” I-arylpiperazinic ligands of 5-HT7 receptor and use thereof
ES2811098T3 (es) 2015-07-02 2021-03-10 Centrexion Therapeutics Corp Citrato de (4-((3r,4r)-3-metoxitetrahidro-pirano-4-ilamino)piperidin-1-il)(5-metil-6-(((2r, 6s)-6-(p-tolil)tetrahidro-2hpirano-2-il) metilamino)pirimidin-4il) metanona

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2985657A (en) * 1959-10-12 1961-05-23 Paul A J Janssen 1-(aroylalkyl)-4-heterocyclylpiperazines
US5001125A (en) * 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines

Also Published As

Publication number Publication date
FI863120A (fi) 1987-02-01
JPS6229575A (ja) 1987-02-07
KR870001192A (ko) 1987-03-12
NO863083D0 (no) 1986-07-30
HU195501B (en) 1988-05-30
IL79549A0 (en) 1986-10-31
DK363186D0 (da) 1986-07-30
ZA865700B (en) 1988-03-30
EP0211457A3 (en) 1987-07-22
FI863120A0 (fi) 1986-07-30
ES8802151A1 (es) 1988-04-01
ZW14886A1 (en) 1988-02-24
CN86105558A (zh) 1987-01-28
PT83098B (en) 1988-07-13
AU6073986A (en) 1987-02-05
HUT41772A (en) 1987-05-28
PH22884A (en) 1989-01-19
DK363186A (da) 1987-02-01
EP0211457A2 (en) 1987-02-25
GR862022B (en) 1986-12-24
TNSN86117A1 (fr) 1990-01-01
NZ216918A (en) 1988-11-29
PT83098A (en) 1986-08-01
NO863083L (no) 1987-02-02

Similar Documents

Publication Publication Date Title
ES555834A0 (es) Un procedimiento para la preparacion de nuevas piranopiridinas.
ES551249A0 (es) Un procedimiento para la preparacion de peptidilaminodioles.
ES556738A0 (es) Un procedimiento para la preparacion de nuevos piridazinaminas.
ES553044A0 (es) Un procedimiento para la preparacion de nuevos derivados de fenoxialquilaminopirimidina.
ES554405A0 (es) Un procedimiento para la preparacion de derivados de aza-indol.
ES556550A0 (es) Un procedimiento para la preparacion de androsta -1-4-dien-3,17-dionas.
ES545464A0 (es) Un procedimiento para la preparacion de tetrahidroftalimidas.
ES540705A0 (es) Un procedimiento para la preparacion de 17b-carbamoil-n-monosustituido -o 17b-acil-4-aza-5-alfa-androstien-3-onas.
ES556127A0 (es) Un procedimiento para la preparacion de quinolinas 2-sustituidas.
ES554983A0 (es) Un procedimiento para la preparacion de silileteres.
ES552189A0 (es) Un procedimiento para la preparacion de derivados de piridimilmidazolidiona.
ES540609A0 (es) Un procedimiento para la preparacion de pirazolo piridinas.
ES540610A0 (es) Un procedimiento para la preparacion de pirazolopiridinas.
ES544521A0 (es) Un procedimiento para la preparacion de triazolobenzodiazefinas.
ES546872A0 (es) Un procedimiento para la preparacion de aminoalcoxibenzopiranonas.
ES552297A0 (es) Un procedimiento para la preparacion de nuevos derivados de disacaridos o trisacaridos.
ES541781A0 (es) Un procedimiento para la preparacion de nuevos benzotiopenos.
ES553874A0 (es) Un procedimiento para la preparacion de metanosulfonatos de dioxolano.
ES555369A0 (es) Un procedimiento para la preparacion de un polialquenoilisocianato.
ES547805A0 (es) Un procedimiento para la preparacion de nuevos derivados de guanina.
ES557772A0 (es) Un procedimiento para la preparacion de epipodofilotoxina
ES547205A0 (es) Un procedimiento para la preparacion de nuevas quinazolindionas.
ES555723A0 (es) Un procedimiento para la preparacion de tetrahidroimidazoquinazolinonas.
ES553703A0 (es) Un procedimiento para la preparacion de vesiculas de fosfoliptidos.
ES542882A0 (es) Un procedimiento para la preparacion de nuevas sulfonilureas.